LLY catalysts
Catalysts and events linked to LLY, newest first.
Do these developments change your position?
Review LLY alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-09-24Eli Lilly Signs Up to $3.35B Drug Discovery Deal With InnoCareLLY
- 2026-09-24InnoCare and Eli Lilly enter multi-target discovery pact worth up to $3.35 billionLLY
- 2026-09-24InnoCare and Eli Lilly Enter Strategic Licensing Deal Worth Up to $3.35BLLY
- 2026-09-24Eli Lilly and InnoCare Enter Collaboration Agreement Valued Up to $3.35BLLY
- 2026-09-23Novo Nordisk Rebrands to Novo and Prepares Oral GLP-1 Launch Against Eli LillyLLY NVO-0.68%
- 2026-09-23Novo Rebrands to 'Novo' and Launches Oral GLP-1 Pill in Obesity Market PushLLY NVO-0.68%
- 2026-09-23Roche Reports 15.5% Weight Loss in Phase II Trial for EnicepatideLLY NVO RHHBY-0.68%
- 2026-09-23Novo Rebrands to 'Novo' and Deploys Oral GLP-1 Pill in Market Share DefenseLLY NVO-0.68%
- 2026-09-23Roche Reports 15.5% Weight Loss in Phase II Trial of Dual GLP-1/GIP Agonist EnicepatideLLY NVO RHHBY-0.68%
- 2026-09-20Twist Bioscience Surges 31% on Eli Lilly AI Drug Discovery DealLLY
- 2026-09-20Twist Bioscience shares gain 31% on Eli Lilly AI drug discovery pactLLY TWST
- 2026-09-20Twist Bioscience shares gain 31% on Eli Lilly AI drug discovery pactLLY TWST
- 2026-09-20Twist Bioscience Surges 31% on Eli Lilly AI Drug Discovery DealLLY TWST
- 2026-09-19Twist Bioscience Partners With Eli Lilly on TuneLab AI Drug DiscoveryLLY
- 2026-09-19Twist Bioscience Partners With Eli Lilly on TuneLab AI Drug DiscoveryLLY TWST
- 2026-09-19Twist Bioscience Partners With Eli Lilly on TuneLab AI Drug DiscoveryLLY TWST
- 2026-09-19Twist Bioscience partners with Eli Lilly on AI-driven TuneLab drug discoveryLLY TWST
- 2026-09-19Twist Bioscience Partners with Eli Lilly on AI Drug Discovery PlatformLLY TWST
- 2026-09-19Twist Bioscience Partners with Eli Lilly on AI-Powered TuneLab PlatformLLY TWST
- 2026-09-19Twist Bioscience Rallies 31% on Eli Lilly AI Drug Discovery CollaborationLLY TWST
- 2026-09-19Twist Bioscience partners with Eli Lilly on TuneLab AI discoveryLLY TWST
- 2026-09-19Twist Bioscience Partners With Eli Lilly on TuneLab AI Drug DiscoveryLLY TWST
- 2026-09-18Eli Lilly H1 GLP-1 sales reach $27.7B as oral obesity pill Foundayo secures PBMsLLY
- 2026-09-18Eli Lilly GLP-1 Franchise Hits $27.7B in H1 2026 as Foundayo Gains PBM CoverageLLY
- 2026-09-18Eli Lilly GLP-1 Revenue Hits $27.7B in 1H 2026 as Oral Foundayo ExpandsLLY
- 2026-09-18Eli Lilly GLP-1 Revenue Hits $27.7B in 1H 2026 as Oral Foundayo ExpandsLLY
- 2026-09-18Eli Lilly posts $27.7B 1H GLP-1 revenue as oral obesity drug Foundayo expandsLLY
- 2026-09-18Eli Lilly GLP-1 Franchise Hits $27.7B in H1 2026 as Foundayo Gains PBM CoverageLLY
- 2026-09-18Eli Lilly GLP-1 revenue reaches $27.7B in H1 2026 as oral obesity drug expands coverageLLY
- 2026-09-18Eli Lilly H1 GLP-1 sales reach $27.7B as oral obesity pill Foundayo secures PBMsLLY
- 2026-09-18Eli Lilly generates $27.7B in 1H GLP-1 sales as Foundayo gains PBM formularyLLY
- 2026-09-18Eli Lilly posts $27.7B 1H GLP-1 revenue as oral obesity drug Foundayo expandsLLY NVO-10.27%
- 2026-09-18Eli Lilly GLP-1 Franchise Hits $27.7B in H1 2026 as Foundayo Gains PBM CoverageLLY NVO-10.27%
- 2026-09-18Eli Lilly H1 GLP-1 sales reach $27.7B as oral obesity pill Foundayo secures PBMsLLY NVO-10.27%
- 2026-09-18Eli Lilly generates $27.7B in 1H GLP-1 sales as Foundayo gains PBM formularyLLY NVO-10.27%
- 2026-09-18Eli Lilly GLP-1 revenue reaches $27.7B in 1H 2026 as oral Foundayo expands PBM coverageLLY XLV+1.37%
- 2026-09-18Eli Lilly GLP-1 Revenue Hits $27.7B in 1H 2026 as Oral Foundayo ExpandsLLY NVO-10.27%
- 2026-09-18Eli Lilly GLP-1 revenue reaches $27.7B in H1 2026 as oral obesity drug expands coverageLLY NVO-10.27%
- 2026-09-17Eli Lilly Expands US Oral GLP-1 Foundayo Prescriptions to 47.5K Against WegovyLLY
- 2026-09-17Eli Lilly Expands US Oral GLP-1 Foundayo Prescriptions to 47.5K Against WegovyLLY
- 2026-09-17Eli Lilly Expands US Oral GLP-1 Foundayo Prescriptions to 47.5K Against WegovyLLY NVO-10.58%
- 2026-09-13Eli Lilly Immunology Revenue Reaches $2.6B in H1 2026 on Taltz and New LaunchesLLY
- 2026-09-13Eli Lilly Immunology Revenue Reaches $2.6B in H1 2026 on Taltz and New LaunchesLLY
- 2026-09-13Eli Lilly Expands Non-Incretin Growth as Immunology Revenue Hits $2.6B in H1LLY
- 2026-09-13Eli Lilly Immunology Division Reaches $2.6 Billion Revenue in H1 2026LLY
- 2026-09-13Eli Lilly Immunology Revenue Hits $2.6B in H1 2026, Growing 9% YoYLLY
- 2026-09-13Eli Lilly Immunology Revenue Hits $2.6B in H1 2026, Growing 9% YoYABBV LLY
- 2026-09-13Eli Lilly Immunology Revenue Reaches $2.6B in H1 2026 on Taltz and New LaunchesABBV LLY
- 2026-09-13Eli Lilly Immunology Division Reaches $2.6 Billion Revenue in H1 2026LLY
- 2026-09-13Eli Lilly Expands Non-Incretin Growth as Immunology Revenue Hits $2.6B in H1ABBV LLY
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.